Details for Patent: 9,474,752
✉ Email this page to a colleague
Title: | Method for treating a pulmonary hypertension condition |
Abstract: | A method for treating a pulmonary hypertension condition such as pulmonary arterial hypertension (PAH) in a subject comprises administering to the subject a therapeutically effective amount of ambrisentan, wherein, at baseline, time from first diagnosis of the condition in the subject is not greater than about 2 years. |
Inventor(s): | Gerber; Michael J. (Denver, CO), Dufton; Christopher (Nederland, CO) |
Assignee: | Gilead Sciences, Inc. (Foster City, CA) |
Filing Date: | Feb 17, 2014 |
Application Number: | 14/182,208 |
Claims: | 1. A method for treating a pulmonary hypertension condition in a human patient, comprising administering to the patient a therapeutically effective amount of ambrisentan and a therapeutically effective amount of an agent selected from the group consisting of sildenafil, tadalafil and vardenafil. 2. The method of claim 1, wherein the pulmonary hypertension condition is pulmonary arterial hypertension (PAH). 3. The method of claim 2, wherein the PAH is of WHO Class II, III or IV. 4. The method of claim 1, wherein the agent is tadalafil. 5. The method of claim 1, wherein the ambrisentan is administered in a daily dosage amount of about 1 mg to about 25 mg. 6. The method of claim 1, wherein the ambrisentan is administered in a daily dosage amount of about 2.5 mg to about 10 mg. 7. The method of claim 1, wherein the ambrisentan and the agent are administered in one dosage form for administration at the same time. 8. The method of claim 1, wherein the ambrisentan and the agent are administered separately at different times. 9. A method for treating pulmonary arterial hypertension (PAH) in a human patient, comprising administering to the patient a therapeutically effective amount of ambrisentan and a therapeutically effective amount of tadalafil. 10. The method of claim 9, wherein the PAH is idiopathic PAH. 11. The method of claim 9, wherein the PAH is of WHO Class II, III or IV. 12. The method of claim 9, wherein the ambrisentan is administered in a daily dosage amount of about 1 mg to about 25 mg. 13. The method of claim 9, wherein the ambrisentan is administered in a daily dosage amount of about 2.5 mg to about 10 mg. 14. The method of claim 13, wherein the ambrisentan and the tadalafil are administered in one dosage form for administration at the same time. 15. The method of claim 13, wherein the ambrisentan and the tadalafil are administered separately at different times. |